Neurocrine Biosciences | NBIX - Debt


Neurocrine Biosciences reported $428.4M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
ALKERMES USD 71.6M 1.08M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Cytokinetics USD 1.2B 338.79M Sep/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Exelixis USD 176.46M 3.38M Sep/2025
Gilead Sciences USD 24.94B 5M Dec/2025
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Incyte USD 40.41M 855K Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Prothena USD 9.08M 699K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Repligen USD 542.21M 146.65M Dec/2025
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Teva Pharmaceutical Industries USD 17.07B 450M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025
Xoma USD 120.79M 3.27M Jun/2024